STRATA Skin pre-announces Q1 2023 revenue $7.3-$7.8M, best Q1 since 2016

STRATA Skin Sciences, Inc.

2023-Q1 EPS reported -$0.08 revenue$7,567,000

Preliminary Q1 2023 revenue $7.3-$7.8 million, strongest first quarter since 2016.
Placed 44 TheraClear X devices in Q1; over 3,000 treatments sold since Jan 2023 launch.
Converted 86 Pharos accounts to XTRAC devices from RaMedical acquisition.
CEO Bob Moccia cites strong sales momentum and expects meaningful revenue impact in 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STRATA Skin Sciences, Inc. reported first fiscal quarter of 2023 results: revenue range of $7.3 - $7.8 million.

Period: first fiscal quarter of 2023
Revenue: range of $7.3 - $7.8 million
Result: preliminary results

Exact text from the filing

--- EX-99.1 2 brhc20051325_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 STRATA Skin Sciences Pre-Announces First Quarter 2023 Results • Preliminary revenue to be within the range of $7.3 - $7.8 million and expected to be the strongest first-quarter results since first quarter of 2016 • Company exceeds plan with 44 TheraClear ® X placements in the first quarter

View on SEC.gov

Browse all earnings releases →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-017913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.